



Theresa PCP Testimonial - Pre-Commercial Procurement of innovative and sustainable solutions to Treat HEalthcaRE System wAstewater

Funded under Horizon Europe ([HORIZON-HLTH-2024-CARE-14-01](#)) and running from 2025 to 2029, the THERESA PCP focuses on the treatment of hospital wastewater.

The main objective of THERESA PCP is to launch a pre-commercial procurement process (PCP) based on the development of an environmentally sustainable on-site system to decontaminate hospital wastewater, being capable of effectively removing, among other contaminants, cytostatic drugs, X-ray contrast agents, antibiotics, antibiotic-resistant bacteria and antibiotic-resistant genes, from hospital wastewater.

The project is coordinated by Navarrabiomed–Fundación Pública Miguel Servet (FMS) and brings together 13 partners from six European countries. The consortium combines the expertise of research institutes, universities, and hospital stakeholders across the healthcare landscape.

ZAS (Ziekenhuis Aan de Stroom) plays an important role in the project by contributing real-world insights from a large and diverse hospital network. As a representative of hospital stakeholders, ZAS provides input on needs, feasibility, and practical constraints within healthcare settings. This ensures that the proposed solutions are relevant, implementable, and aligned with the realities of clinical practice. For more information about ZAS, you can visit our website via the following [link](#).

The PCP is structured into three phases. We are currently in Phase 0. This concerns preliminary actions and a technical dialogue with industry. During the first months of the project, Theresa's partners work on the specification and definition of needs. The results lead to an Open Market Consultation and a Call for Tenders. This has already generated substantial feedback and interest from industry stakeholders.

As of March 2027, we will transition to Phase 1, focusing on solution design. This will be followed by Phase 2 (prototype development) and Phase 3 (operational validation).

We are confident that this will lead to the development of innovative and sustainable technologies that enhance the treatment of hospital wastewater, thereby contributing positively to biodiversity and public health.



[Website](#)



[LinkedIn](#)



[YouTube](#)



theresa 

